started · updated
BRAIN Biotech AG appoints Dr. Sven K. Weber as CEO effective Oct 1, 2026
BRAIN Biotech AG announced that its Supervisory Board has appointed Dr. Sven K. Weber as Chairman of the Executive Board (CEO), effective 1 October 2026, for a three‑year term. He succeeds Adriaan Moelker, who will step down on 30 September 2026 after six years as CEO and will retire at the end of his contract, remaining a senior advisor until January 2027.
Dr. Weber, 44, previously held senior positions at BASF SE, most recently as Vice President of the Global Business Unit Feed Enzymes & Feed Performance Ingredients, and earlier roles in automotive and contract‑research divisions. He holds a chemistry diploma and a doctorate from the University of Heidelberg and completed an executive program at the SGMI Management Institute.
Dr. Michael Majerus, Chairman of BRAIN’s Supervisory Board, said the change will continue the company’s strategic direction and accelerate growth in the enzyme sector.
Entities
Adriaan Moelker · BASF SE · BRAIN Biotech AG · Dr. Michael Majerus · Dr. Sven K. Weber · Zwingenberg, Germany
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Dr. Michael Majerus is Chairman of the Supervisory Board of BRAIN Biotech AG. www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] Dr. Weber has held leadership positions at BASF SE since 2011, most recently as Vice President of the global enzyme business. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 2 SOURCES] Dr. Weber holds a diploma in chemistry and a doctorate from the University of Heidelberg. www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] Dr. Sven K. Weber was appointed Chairman of the Executive Board (CEO) of BRAIN Biotech AG, effective 1 October 2026. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] Adriaan Moelker will retire as CEO on 30 September 2026 after six years in the role. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [○ 1 SOURCE] Dr. Weber will serve a three‑year term as CEO of BRAIN Biotech AG. biotech-investments.com
- [● 3 SOURCES] Moelker will continue as a senior advisor to BRAIN Biotech AG until January 2027. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] Adriaan Moelker will remain a senior advisor to BRAIN Biotech AG until January 2027. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] The appointment will be for a three‑year term starting 1 October 2026. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 2 SOURCES] Dr. Sven K. Weber previously held senior positions at BASF SE, including Vice President of the Global Business Unit Feed Enzymes & Feed Performance Ingredients. www.webdisclosure.com · www.newmediawire.com
- [● 3 SOURCES] The appointment was announced on 29 July 2026. biotech-investments.com · www.webdisclosure.com · www.newmediawire.com
- [● 2 SOURCES] Dr. Sven K. Weber holds a diploma in chemistry and a doctorate from the University of Heidelberg. www.webdisclosure.com · www.newmediawire.com